Dr. S. Eralp Bellibas

Dr. S. Eralp Bellibaş is a distinguished physician scientist with a remarkable career spanning academia, research, and the pharmaceutical industry. He graduated from Ankara University School of Medicine, specialized in Pharmacology at Ege University, and completed Clinical Pharmacology post-doctoral training at the University of California, San Francisco School of Medicine.  His career includes significant roles such as a visiting researcher at the University of Milan, a founding faculty member at Adnan Menderes University, and a key contributor to the establishment of the Ege University Drug Research and Development Center (ARGEFAR).

Dr. Bellibaş has been recognized for his contributions with numerous awards, including Turkey's most successful young researcher in Medicine by the Junior Chamber International (JCI) and Hürriyet Newspaper in 1996, and the International Clinical Pharmacology Fellowship Award by Merck Foundation in 1997. His industrial career includes pivotal roles at Roche Pharmaceuticals, Johnson & Johnson, Novartis Pharmaceuticals, and Parexel. He has been instrumental in the development of several first-in-class FDA-approved drugs, such as Fuzeon®, Exelon Patch®, Orbactiv®, Kengreal®, and Leqvio®. His contributions to the Fuzeon® team earned him the Roche Olympiads Gold Medal Award in 2002, and Orbactiv® was nominated for the Galien Award in 2015.

In addition to his industrial achievements, Dr. Bellibaş has an extensive publication record which has been cited in over 600 international publications, including citations in Goodman & Gilman's The Pharmacological Basis of Therapeutics. He has edited the Rational Drug Guide of Turkey and served on the editorial board of the journal Drugs in R&D. He has developed the INDDose® a smartphone application for calculating starting doses in first-in-human studies and made it freely available for drug developers. He is actively involved in various professional organizations including American Heart Association and American College of Clinical Pharmacology and serves on advisory board in the IQ Consortium representing pharmaceutical and biotechnology companies contributing to the advancement of drug development and clinical research globally.